IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
32.18
-1.01 (-3.04%)
At close: Oct 29, 2025, 4:00 PM EDT
31.67
-0.51 (-1.59%)
After-hours: Oct 29, 2025, 7:38 PM EDT
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 15 analysts that cover IDEAYA Biosciences stock have a consensus rating of "Buy" and an average price target of $48.2, which forecasts a 49.78% increase in the stock price over the next year. The lowest target is $27 and the highest is $79.
Price Target: $48.2 (+49.78%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Buy | 7 | 8 | 8 | 8 | 11 | 11 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 15 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $74 → $79 | Buy | Maintains | $74 → $79 | +145.49% | Oct 23, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $27 → $30 | Hold | Maintains | $27 → $30 | -6.77% | Oct 21, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $38 → $41 | Buy | Maintains | $38 → $41 | +27.41% | Oct 21, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $62 | Strong Buy | Reiterates | $62 | +92.67% | Oct 21, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +55.38% | Sep 18, 2025 |
Financial Forecast
Revenue This Year
13.31M
from 7.00M
Increased by 90.17%
Revenue Next Year
42.52M
from 13.31M
Increased by 219.42%
EPS This Year
-3.18
from -3.36
EPS Next Year
-3.45
from -3.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.6M | 176.4M | |||
| Avg | 13.3M | 42.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 365.0% | 1,224.7% | |||
| Avg | 90.2% | 219.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -2.63 | |||
| Avg | -3.18 | -3.45 | |||
| Low | -3.60 | -4.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.